# The ctDNA for Evaluating Whether to Use Adjuvant Therapy After SBRT in Patients With Early Lung Cancer

> **NCT05411809** · NA · NOT_YET_RECRUITING · sponsor: **Peking University Third Hospital** · enrollment: 180 (estimated)

## Conditions studied

- Stereotactic Body Radiation Therapy

## Interventions

- **DRUG:** drug adjuvant therapy

## Key facts

- **NCT ID:** NCT05411809
- **Lead sponsor:** Peking University Third Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2022-06-15
- **Primary completion:** 2024-06-15
- **Final completion:** 2027-05-15
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2022-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05411809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05411809, "The ctDNA for Evaluating Whether to Use Adjuvant Therapy After SBRT in Patients With Early Lung Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05411809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*